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Some of these data were presented in Advances in Science as an abstract at the European Society of Cardiology Congress, August 27 to 31, 2016, in Rome, Italy.

Introduction {#jah32051-sec-0005}
============

During the past decade, mounting evidence has indicated that ambulatory blood pressure (BP) monitoring (ABPM) provides various details on BP profiles, including the average 24‐hour BP, daytime and nighttime BP, and circadian variability, which is superior to clinical BP for the diagnosis and prognostic evaluation of hypertensive individuals.[1](#jah32051-bib-0001){ref-type="ref"}, [2](#jah32051-bib-0002){ref-type="ref"}, [3](#jah32051-bib-0003){ref-type="ref"}, [4](#jah32051-bib-0004){ref-type="ref"} As such, current guidelines recommend the use of ABPM in routine clinical practice.[5](#jah32051-bib-0005){ref-type="ref"}

Recent studies have demonstrated that morning hypertension is associated with target organ damage and adverse cardiovascular outcomes in patients with hypertension.[6](#jah32051-bib-0006){ref-type="ref"}, [7](#jah32051-bib-0007){ref-type="ref"}, [8](#jah32051-bib-0008){ref-type="ref"}, [9](#jah32051-bib-0009){ref-type="ref"} The Japan Morning Surge Home Blood Pressure (J‐HOP) study reported that morning systolic BP (SBP) was closely related to subclinical target organ damage indicators, such as urine albumin/creatinine ratio and pulse wave velocity (PWV).[7](#jah32051-bib-0007){ref-type="ref"} In the Home Blood Pressure Measurement With Olmesartan Naive Patients to Establish Standard Target Blood Pressure (HONEST) registry, in a cohort of 21 591 patients with essential hypertension, morning hypertension (morning home BP ≥145 mm Hg) was associated with adverse cardiovascular outcomes, even among patients with well‐controlled clinical BP.[8](#jah32051-bib-0008){ref-type="ref"}, [9](#jah32051-bib-0009){ref-type="ref"}

Patients with morning hypertension could be categorized as either those with nocturnal hypertension who have sustained hypertension upon awakening or those without nocturnal hypertension who have morning hypertension upon awakening. Previous studies have shown that both nocturnal hypertension and early morning BP surge are associated with a higher risk of target organ damage and cardiovascular disease (CVD).[6](#jah32051-bib-0006){ref-type="ref"}, [8](#jah32051-bib-0008){ref-type="ref"} However, it is unclear whether morning hypertension associated with sustained nocturnal hypertension and that associated with morning BP surge differ in terms of their effects on cardiovascular target organ damage and clinical outcomes. In the present study, we aimed to determine the association of morning hypertension with or without nocturnal hypertension with vascular target organ damage and central hemodynamics in a prospective cohort of patients at high risk for CVD.

Methods {#jah32051-sec-0006}
=======

Study Participants {#jah32051-sec-0007}
------------------

The participants were enrolled in a South Korean government--sponsored prospective cohort study (Cardiovascular and Metabolic Disease Etiology Research Center--High Risk Cohort \[CMERC‐HI\]; clinicaltrials.gov: NCT02003781). The institutional review board at Yonsei University College of Medicine approved the study (2013‐0752‐027), and all participants provided informed consent. The inclusion criteria were as follows: patients with high‐risk hypertension, diabetes mellitus with albuminuria, anuric end‐stage renal disease, and use of dialysis (urine output \<200 mL/d); relatives of acute myocardial infarction patients who were younger than 55 years (for men) or 65 years (for women); patients with asymptomatic atherosclerotic CVD (abdominal aorta diameter ≥3 cm or ankle‐brachial index \<0.9, carotid plaque or carotid intima‐media thickness ≥0.9 mm, asymptomatic old cerebrovascular accident, or \>30% stenosis in at least 1 major coronary artery); rheumatic arthritis patients aged older than 40 years taking methotrexate and steroids; atrial fibrillation patients with a CHA2DS~2~‐VASc score ≥1; and kidney transplant recipients who underwent transplantation more than 3 months previously. The exclusion criteria were histories of acute coronary syndrome, symptomatic coronary artery disease, symptomatic peripheral artery disease, and heart failure; desired life expectancy less than 6 months because of non‐CVD; pregnancy or breastfeeding; and histories of contrast allergy and related side effects. The present study included 1070 consecutive patients from the CMERC‐HI cohort in whom ABPM was performed, and markers for vascular damage and central hemodynamics were assessed between December 2013 and February 2016. Patients with end‐stage renal disease and those who underwent kidney transplantation were excluded in this study.

Clinical and Anthropometric Measurements {#jah32051-sec-0008}
----------------------------------------

All participants underwent baseline evaluations, including an initial standardized questionnaire. Height, weight, body mass index, anthropometric data, and sitting brachial BP were measured (HEM 7080‐IC, Omron, Japan). Sitting brachial BP was measured after 5 minutes of rest in the right arm 3 times at 2‐minute intervals. The mean of the 3 values was used for analysis. Total cholesterol, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, triglycerides, and glucose levels were measured in blood samples obtained after a 12‐hour fast. A resting 12‐lead ECG was obtained using the GE Marquette MUSE system (GE Medical Systems, Milwaukee, WI). Participants were considered to be smokers if they were current or former smokers. Participants were considered to have dyslipidemia if they had high total cholesterol (\>200 mg/dL), high low‐density lipoprotein cholesterol (\>160 mg/dL), low high‐density lipoprotein cholesterol (\<40 mg/dL for men, \<50 mg/dL for women), or high triglyceride (\>150 mg/dL) levels, or if they were currently using lipid‐lowering drugs. Participants were considered to have diabetes mellitus if they had a history of diabetes mellitus, were receiving antidiabetic treatment, or had fasting plasma glucose levels of \>126 mg/dL. Participants were considered to have hypertension if they had a self‐reported history of hypertension, a history of antihypertensive medication use, or a BP of ≥140/90 mm Hg at the visit time.

Ambulatory BP Monitoring {#jah32051-sec-0009}
------------------------

Twenty‐four--hour ABPM was performed using the Takeda TM‐2430 instrument (A&D Medical, Tokyo, Japan), with readings taken every 30 minutes. Daytime and nighttime periods were defined according to information provided by the patient. Ambulatory BP readings were averaged for 24‐hour, daytime, and nighttime values. Patients were classified according to dipping pattern as follows: dippers (nighttime BP decrease \>10%), nondippers (nighttime BP decrease \<10% and \>0%), and reverse dippers (nighttime BP \> daytime BP). Morning BP was defined as the average BP of 4 measurements taken after awakening. Morning hypertension was defined as a morning BP \>135/85 mm Hg. Nocturnal hypertension was defined as an average nighttime BP \>120/70 mm Hg, as previously defined.[5](#jah32051-bib-0005){ref-type="ref"} The study participants were grouped according to the morning BP as follows: subtype I group, patients with normal morning BP; subtype II group, patients with morning hypertension and normal nocturnal BP; and subtype III group, patients with morning hypertension and nocturnal hypertension.

Measurement of Vascular Target Organ Damage and Central Hemodynamics {#jah32051-sec-0010}
--------------------------------------------------------------------

All study patients underwent pulse wave measurement, ankle‐brachial index assessment, coronary calcium scan, carotid to femoral PWV (cfPWV), and central BP measurement in the morning. The brachial to ankle PWV (baPWV) and ankle‐brachial index were determined using a validated oscillometric device (VP‐1000 plus/VP‐2000, Omron, Japan), as previously described.[10](#jah32051-bib-0010){ref-type="ref"}, [11](#jah32051-bib-0011){ref-type="ref"} Briefly, after an overnight fast and 5 minutes of rest, the cfPWV was measured in the supine position in a quiet, temperature‐controlled room using a SphygmoCor device (AtCor Medical, West Ryde, Australia), as previously described.[10](#jah32051-bib-0010){ref-type="ref"} Central hemodynamics were evaluated in the sitting position after 10 minutes of rest using a commercially available radial artery tonometry device (SphygmoCor), as previously described.[10](#jah32051-bib-0010){ref-type="ref"}, [12](#jah32051-bib-0012){ref-type="ref"} Briefly, using a high‐fidelity micromanometer (Millar Instruments, Houston, TX), peripheral pressure waveforms were recorded from the radial artery at the wrist, as previously reported. Central SBP, diastolic BP (DBP), pulse pressure, augmentation pressure, forward wave amplitude, and the augmentation index (AIx) were acquired from pulse waveform analysis. Pulse pressure was calculated as the difference between systolic and diastolic pressure. Augmentation pressure was defined as the difference between the second and first systolic peak pressures, and the AIx was defined as the ratio of augmentation pressure to aortic pulse pressure. The AIx was normalized for a heart rate of 75 beats per minute (AIx at 75/min), as this measurement is influenced by heart rate.

Coronary Artery Calcium Scan {#jah32051-sec-0011}
----------------------------

All examinations were performed using a 320‐row computed tomographic system (Aquilion ONE; Toshiba Medical Systems, Tokyo, Japan) with patients in the supine position on a table, and images were acquired during a single breath hold, which allows image reconstruction in a single cardiac phase. Dual scanograms were used for planning the examination and determining the anatomical range to be covered. A nonenhanced prospective ECG‐gated scan was performed to measure the coronary artery calcium score (CACS) with the following parameters: rotation time, 275 ms; slice collimation, 0.5 mm; slice width, 3.0 mm; tube voltage, 100 kV; and automatic tube current modulation (SURE Exposure 3D standard, Toshiba Medical Systems Corporation, Otawara, Japan). Images were analyzed in a core workstation using dedicated software (TeraRecon version 4.4.11.82.3430.Beta, Foster City, CA). Agatston calcium scores were calculated to quantify the extent of coronary artery calcification.[13](#jah32051-bib-0013){ref-type="ref"}, [14](#jah32051-bib-0014){ref-type="ref"}

Statistical Analysis {#jah32051-sec-0012}
--------------------

Continuous variables are summarized as mean±SD, and categorical variables are summarized as a percentage of the group total. Non‐normally distributed variables were log transformed for statistical analyses. Continuous variables were compared using independent *t* tests or the Mann--Whitney *U* test for non‐normally distributed variables if needed. Multivariate logistic regression analysis was performed in a model using known cardiovascular risk factors and confounding variables. A 2‐tailed *P*\<0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 22.0 software (IBM Corp, Armonk, NY).

Results {#jah32051-sec-0013}
=======

Clinical Characteristics and Laboratory Findings {#jah32051-sec-0014}
------------------------------------------------

Among the 1070 patients, 601 (56.2%), 95 (8.9%), and 374 (34.9%) were included in the subtype I, subtype II, and subtype III groups, respectively. Among 469 patients with morning hypertension, 79.7% showed an associated with nocturnal hypertension. In 222 uncontrolled hypertensive patients, according to the clinical BP target, 64.0% showed morning hypertension and 55.4% showed morning hypertension with nocturnal hypertension (subtype III). Baseline characteristics of the study patients are summarized in Table [1](#jah32051-tbl-0001){ref-type="table-wrap"}. The mean age of patients was greater in the subtype II group than in the subtype I group; however, there were no significant differences in male prevalence among the 3 groups. Waist circumference and body mass index were significantly higher in the subtype II and III groups than in the subtype I group. Office brachial BP was significantly higher in the subtype III group than in the subtype I and II groups. In addition, the prevalence of diabetes mellitus and chronic kidney disease was higher in the subtype III group than in the subtype I and II groups. Moreover, β‐blockers and calcium channel blockers were more commonly used and serum blood urea nitrogen levels, creatinine levels, and albumin/creatinine ratio were significantly higher in the subtype III group than in the subtype I and II groups.

###### 

Baseline Characteristics of the Study Participants

                                      Subtype I (n=601)   Subtype II (n=95)                                 Subtype III (n=374)                                                                         *P* Value
  ----------------------------------- ------------------- ------------------------------------------------- ------------------------------------------------------------------------------------------- -----------
  Age, y                              60±11               63±11[a](#jah32051-note-0004){ref-type="fn"}      62±10                                                                                       0.003
  Men, No. (%)                        342 (56.9)          45 (47.4)                                         210 (56.1)                                                                                  0.217
  Waist conference, cm                86±9                89±9[a](#jah32051-note-0004){ref-type="fn"}       89±9[a](#jah32051-note-0004){ref-type="fn"}                                                 \<0.001
  Body mass index, kg/m^2^            25.0±3.5            26.0±3.5[a](#jah32051-note-0004){ref-type="fn"}   25.9±3.4[a](#jah32051-note-0004){ref-type="fn"}                                             \<0.001
  SBP, mm Hg                          123±13              126±15                                            134±17[a](#jah32051-note-0004){ref-type="fn"}, [b](#jah32051-note-0005){ref-type="fn"}      \<0.001
  DBP, mm Hg                          75±9                72±8[a](#jah32051-note-0004){ref-type="fn"}       77±11[a](#jah32051-note-0004){ref-type="fn"}, [b](#jah32051-note-0005){ref-type="fn"}       \<0.001
  Heart rate, beat per min            69±11               66±11                                             67±12                                                                                       0.047
  Smoker, No. (%)                     267 (44.4)          40 (42.1)                                         180 (48.1)                                                                                  0.414
  Hypertension, No. (%)               499 (83.0)          81 (85.3)                                         330 (88.2)                                                                                  0.085
  Diabetes mellitus, No. (%)          188 (31.3)          27 (28.4)                                         158 (42.2)                                                                                  0.001
  Hypercholesterolemia, No. (%)       347 (57.7)          59 (62.1)                                         215 (57.5)                                                                                  0.700
  Cerebrovascular accident, No. (%)   25 (3.5)            3 (2.8)                                           13 (2.5)                                                                                    0.593
  Chronic kidney disease, No. (%)     132 (22.0)          12 (12.6)                                         94 (25.1)                                                                                   0.032
  CVD family history, No. (%)         176 (29.3)          25 (26.3)                                         83 (22.2)                                                                                   0.051
  ACEI/ARB, No. (%)                   251 (41.8)          46 (48.4)                                         156 (41.7)                                                                                  0.454
  β‐Blocker, No. (%)                  119 (19.8)          20 (21.1)                                         115 (30.7)                                                                                  \<0.001
  Calcium channel blocker, No. (%)    205 (34.1)          40 (42.1)                                         176 (47.1)                                                                                  \<0.001
  Diuretics, No. (%)                  81 (13.5)           22 (23.2)                                         60 (16.0)                                                                                   0.044
  Aspirin, No. (%)                    160 (26.6)          35 (36.8)                                         113 (30.2)                                                                                  0.093
  Statin, No. (%)                     250 (41.6)          47 (49.5)                                         149 (39.8)                                                                                  0.235
  Glucose, mg/dL                      109±28              108±21                                            113±30                                                                                      0.040
  Total cholesterol, mg/dL            174±38              171±32                                            171±32                                                                                      0.439
  Blood urea nitrogen, mg/dL          19.5±9.3            18.0±8.6                                          20.7±10.3[a](#jah32051-note-0004){ref-type="fn"}, [b](#jah32051-note-0005){ref-type="fn"}   0.033
  Creatinine, mg/dL                   1.1±0.6             1.0±0.6                                           1.2±0.7[b](#jah32051-note-0005){ref-type="fn"}                                              0.005
  eGFR, mL/min per 1.73 m^2^          77±30               84±31                                             72±29[a](#jah32051-note-0004){ref-type="fn"}, [b](#jah32051-note-0005){ref-type="fn"}       \<0.001
  ACR, mg/g (n=753)                   32±81               15±33                                             52±98[a](#jah32051-note-0004){ref-type="fn"}, [b](#jah32051-note-0005){ref-type="fn"}       0.001

Data are presented as mean±SD or number (percentage). ACEI/ARB indicates angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker; ACR, albumin/creatinine ratio; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.

*P*\<0.05 by *t* test (subtype II or III vs I).

*P*\<0.05 by *t* test (subtype III vs II).

ABPM Data {#jah32051-sec-0015}
---------

The 24‐hour average SBP/DBP, daytime average SBP/DBP, and nighttime average SBP/DBP were significantly higher in the subtype III group than in the subtype I and II groups (Table [2](#jah32051-tbl-0002){ref-type="table-wrap"}). As expected, considering the definition of the morning hypertension subtypes, the subtype II group had a significantly higher proportion of patients with extreme dippers and dippers, whereas the subtype III group had a significantly higher proportion of patients with nondippers and reverse dippers. In addition, nocturnal trough SBP was higher in the subtype III group than in the subtype I and II groups, whereas the prevalence and degree of morning BP surge were higher in the subtype II group than in the subtype I group.

###### 

Ambulatory BP Monitoring Data in Terms of Morning Hypertension Subtypes

                                Subtype I    Subtype II                                      Subtype III                                                                              *P* Value
  ----------------------------- ------------ ----------------------------------------------- ---------------------------------------------------------------------------------------- -----------
  Total SBP, mm Hg              122±10       125±14                                          141±11[a](#jah32051-note-0007){ref-type="fn"}, [b](#jah32051-note-0008){ref-type="fn"}   \<0.001
  Total DBP, mm Hg              75±7         74±5                                            82±10[a](#jah32051-note-0007){ref-type="fn"}, [b](#jah32051-note-0008){ref-type="fn"}    \<0.001
  Day SBP, mm Hg                127±101      135±10[a](#jah32051-note-0007){ref-type="fn"}   145±12[a](#jah32051-note-0007){ref-type="fn"}, [b](#jah32051-note-0008){ref-type="fn"}   \<0.001
  Day DBP, mm Hg                78±7         80±7                                            85±9[a](#jah32051-note-0007){ref-type="fn"}, [b](#jah32051-note-0008){ref-type="fn"}     \<0.001
  Night SBP, mm Hg              113±12       111±8                                           133±13[a](#jah32051-note-0007){ref-type="fn"}, [b](#jah32051-note-0008){ref-type="fn"}   \<0.001
  Night DBP, mm Hg              69±8         65±3[a](#jah32051-note-0007){ref-type="fn"}     77±7[a](#jah32051-note-0007){ref-type="fn"}, [b](#jah32051-note-0008){ref-type="fn"}     \<0.001
  Extreme dipper                74 (12.3)    33 (34.7)                                       15 (4.0)                                                                                 \<0.001
  Dipper                        249 (41.1)   49 (51.6)                                       139 (37.2)                                                                               0.035
  Nondipper                     234 (38.9)   13 (13.7)                                       167 (44.7)                                                                               \<0.001
  Reverse dipper                44 (7.3)     0 (0)                                           53 (14.2)                                                                                \<0.001
  Morning peak SBP, mm Hg       135±15       169±20[a](#jah32051-note-0007){ref-type="fn"}   165±19[a](#jah32051-note-0007){ref-type="fn"}                                            \<0.001
  Morning mean SBP, mm Hg       122±10       144±7[a](#jah32051-note-0007){ref-type="fn"}    150±12[a](#jah32051-note-0007){ref-type="fn"}, [b](#jah32051-note-0008){ref-type="fn"}   \<0.001
  Nocturnal trough SBP, mm Hg   104±14       101±12                                          123±15[a](#jah32051-note-0007){ref-type="fn"}, [b](#jah32051-note-0008){ref-type="fn"}   \<0.001
  Morning BP surge, mm Hg       18±14        43±14[a](#jah32051-note-0007){ref-type="fn"}    28±16[a](#jah32051-note-0007){ref-type="fn"}, [b](#jah32051-note-0008){ref-type="fn"}    \<0.001
  Morning BP surge, No. (%)     214 (35.6)   87 (91.6)                                       224 (59.9)                                                                               \<0.001

Data are presented as mean±SD or number (percentage). BP indicates blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.

*P*\<0.05 by *t* test (subtype II or III vs I).

*P*\<0.05 by *t* test (subtype III vs II).

Indices of PWV and Central Hemodynamics {#jah32051-sec-0016}
---------------------------------------

The proportion of patients with high‐risk cfPWV, defined as a value \>10 m/s, recommended by the current guidelines,[5](#jah32051-bib-0005){ref-type="ref"} was significantly higher in the subtype III group than in the subtype I and II groups. In addition, the heart to carotid PWV, heart to femoral PWV, femoral to ankle PWV, baPWV, and central SBP and DBP were significantly higher in the subtype III group than in the subtype I and II groups. The AIx was higher in the subtype III group than in the subtype I group. The central SBP and cfPWV were higher in the subtype II group than in the subtype I group; however, there were no significant differences in the PWV indices between the 2 groups ([Figure](#jah32051-fig-0001){ref-type="fig"} and Table [3](#jah32051-tbl-0003){ref-type="table-wrap"}).

![Central hemodynamic parameters according to morning hypertension subtypes. A, Central systolic blood pressure (SBP), (B) central diastolic blood pressure (DBP), (C) carotid‐femoral pulse wave velocity (PWV). Subtype I indicates morning normotension; subtype II, morning hypertension without nocturnal hypertension; subtype III, morning hypertension with nocturnal hypertension.](JAH3-6-e005424-g001){#jah32051-fig-0001}

###### 

PWV and Indices of Central Hemodynamics According to Morning Hypertension Subtypes

                                  Subtype I    Subtype II                                       Subtype III                                                                                *P* Value
  ------------------------------- ------------ ------------------------------------------------ ------------------------------------------------------------------------------------------ -----------
  PWV and ABI                                                                                                                                                                              
  hcPWV, cm/s                     920±400      891±310                                          989±346[a](#jah32051-note-0010){ref-type="fn"}                                             0.008
  hfPWV, cm/s                     1020±298     1032±354                                         1123±357[a](#jah32051-note-0010){ref-type="fn"}, [b](#jah32051-note-0011){ref-type="fn"}   \<0.001
  Mean faPWV, cm/s                1054±281     1016±176                                         1087±220[b](#jah32051-note-0011){ref-type="fn"}                                            0.028
  Mean baPWV, cm/s                1461±267     1500±277                                         1603±304[a](#jah32051-note-0010){ref-type="fn"}, [b](#jah32051-note-0011){ref-type="fn"}   \<0.001
  baPWV \>1800 cm/s, No. (%)      64 (10.8)    12 (12.6)                                        72 (19.5)                                                                                  0.001
  ABI                             1.13±0.08    1.13±0.09                                        1.14±0.09[a](#jah32051-note-0010){ref-type="fn"}                                           0.046
  ABI \<0.9, No. (%)              8 (1.3)      4 (4.2)                                          10 (2.7)                                                                                   0.110
  Central hemodynamics                                                                                                                                                                     
  SBP, mm Hg                      115±15       120±17[a](#jah32051-note-0010){ref-type="fn"}    127±18[a](#jah32051-note-0010){ref-type="fn"}, [b](#jah32051-note-0011){ref-type="fn"}     \<0.001
  DBP, mm Hg                      75±9         74±8                                             78±11[a](#jah32051-note-0010){ref-type="fn"}, [b](#jah32051-note-0011){ref-type="fn"}      \<0.001
  AIx                             27.4±13.2    30.3±12.8                                        30.2±10.7[a](#jah32051-note-0010){ref-type="fn"}                                           0.002
  cfPWV, m/s                      8.8±1.9      9.4±2.3[a](#jah32051-note-0010){ref-type="fn"}   10.0±2.4[a](#jah32051-note-0010){ref-type="fn"}                                            \<0.001
  cfPWV \>10 m/s, No. (%)         112 (20.7)   27 (30.3)                                        127 (39.6)                                                                                 \<0.001
  cfPWV \>12 m/s, No. (%)         34 (6.3)     9 (10.1)                                         62 (19.3)                                                                                  \<0.001
  Central hypertension, No. (%)   97 (17.9)    24 (27.0)                                        148 (46.1)                                                                                 \<0.001

Data are presented as mean±SD or number (percentage). ABI indicates ankle‐brachial index; AIx, augmentation index; baPWV, brachial to ankle pulse wave velocity; cfPWV, carotid to femoral pulse wave velocity; DBP, diastolic blood pressure; faPWV, femoral to ankle pulse wave velocity; hcPWV, heart to carotid pulse wave velocity; hfPWV, heart to femoral pulse wave velocity; PWV, pulse wave velocity; SBP, systolic blood pressure.

*P*\<0.05 by *t* test (subtype II or III vs I).

*P*\<0.05 by *t* test (subtype III vs II).

Coronary Artery Calcium Score {#jah32051-sec-0017}
-----------------------------

The CACS was higher in patients in the subtype III group than in the subtype I and II groups; however, there was no significant difference in the CACS between the patients in the subtype I and II groups (Table [S1](#jah32051-sup-0001){ref-type="supplementary-material"}). We defined a high‐risk CACS using different CACS cutoffs (300, 400, and 1000 AU); however, we did not note any significant difference in the prevalence of high‐risk CACS when considering any of the CACS cutoffs among the subtypes.

Adjusted Logistic Regression Analysis {#jah32051-sec-0018}
-------------------------------------

As demonstrated in Tables [1](#jah32051-tbl-0001){ref-type="table-wrap"} through [3](#jah32051-tbl-0003){ref-type="table-wrap"}, there were significant differences in the baseline characteristics and measurements among the subtypes. As such, we adjusted for confounding factors to determine the independent role of the morning hypertension subtype in a multivariate regression model. First, for predicting central hypertension, defined as central SBP \>130 mm Hg or DBP \>90 mm Hg, suggested by a recent study,[15](#jah32051-bib-0015){ref-type="ref"} subtype III (versus subtype I) was an independent predictor in the fully adjusted model (*P*\<0.001, model Y; Table [4](#jah32051-tbl-0004){ref-type="table-wrap"}). This independence remained significant even after further adjusting with daytime average SBP (*P*=0.013, model Y+day SBP; Table [4](#jah32051-tbl-0004){ref-type="table-wrap"}) and cfPWV level (*P*\<0.001, model Y+cfPWV; Table [S2](#jah32051-sup-0001){ref-type="supplementary-material"}). Second, we adjusted the regression analysis for predicting high‐risk cfPWV (\>10 m/s), as defined by a recent guideline.[5](#jah32051-bib-0005){ref-type="ref"} In the same model (model Y), subtype III was an independent predictor for high‐risk cfPWV (*P*=0.018, Table [5](#jah32051-tbl-0005){ref-type="table-wrap"}). There was a tendency towards significant association after further adjusting with daytime average SBP (*P*=0.104, model Y+day SBP, Table [5](#jah32051-tbl-0005){ref-type="table-wrap"}). However, when we divided the patients into two groups according to median heart rate (high, ≤65 beats per minute or low, \>65 beats per minute), morning hypertension subtype III (versus subtype I) was associated with high‐risk cfPWV in only the high heart rate group (*P*=0.045 for high heart rate versus *P*=0.932 for low heart rate, *P* for interaction=0.023, model Y+day SBP; Table [S3](#jah32051-sup-0001){ref-type="supplementary-material"}). When we selected a different cutoff of high‐risk cfPWV (eg, \>12 m/s), the independent association of subtype III remained significant (*P*=0.026, Table [S4](#jah32051-sup-0001){ref-type="supplementary-material"}). We then analyzed the prediction of each vascular damage marker (CACS \>300 AU, ankle‐brachial index \<0.9, and baPWV \>1800 cm/s). However, we could not find any independent associations of subtype III (versus subtype I or II) after adjustment (Table [S5](#jah32051-sup-0001){ref-type="supplementary-material"}). In summary, there were independent associations of subtype III with the parameters of central hemodynamics and aortic cfPWV. However, there were no significant associations of morning hypertension subtypes with the coronary calcium score and baPWV after adjustment.

###### 

Multivariate Logistic Regression Analysis for Central Hypertension

                              OR (95% CI)            *P* Value
  --------------------------- ---------------------- -----------
  Model Y                                            
  Age, y                      1.024 (1.004--1.044)   0.019
  Brachial SBP, mm Hg         1.104 (1.086--1.123)   \<0.001
  Heart rate, beats per min   0.975 (0.957--0.992)   0.005
  ACEI/ARB                    1.687 (1.115--2.552)   0.013
  Subtype II vs I             1.253 (0.662--2.369)   0.489
  Subtype III vs I            2.249 (1.523--3.322)   \<0.001
  Model Y+day SBP                                    
  Age, y                      1.024 (1.004--1.044)   0.017
  Brachial SBP, mm Hg         1.101 (1.082--1.119)   \<0.001
  Heart rate, beats per min   0.976 (0.958--0.994)   0.008
  ACEI/ARB                    1.728 (1.141--2.619)   0.010
  Subtype II vs I             1.134 (0.594--2.167)   0.703
  Subtype III vs I            1.806 (1.133--2.881)   0.013

Model Y includes age, sex, body mass index, brachial systolic blood pressure (SBP), heart rate, hypertension, hypercholesterolemia, diabetes mellitus, family history of cardiovascular disease, smoking, angiotensin‐converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ACE) use, calcium channel blocker use, β‐blocker use, diuretic use, statin use, aspirin use, blood urea nitrogen, creatinine, glucose, and cholesterol. Central hypertension is defined as central SBP ≥130 mm Hg or central diastolic blood pressure ≥90 mm Hg. OR indicates odds ratio.

###### 

Multivariate Logistic Regression Analysis for High‐Risk cfPWV (10 m/s)

                              OR (95% CI)            *P* Value
  --------------------------- ---------------------- -----------
  Model Y                                            
  Age, y                      1.099 (1.075--1.123)   \<0.001
  Body mass index, kg/m^2^    1.058 (1.004--1.114)   0.034
  Brachial SBP, mm Hg         1.044 (1.031--1.057)   \<0.001
  Heart rate, beats per min   1.044 (1.027--1.062)   \<0.001
  Diabetes mellitus           1.651 (1.097--2.487)   0.016
  locker                      1.600 (1.019--2.514)   0.041
  Creatinine, mg/dL           2.273 (1.292--3.997)   0.004
  Subtype II vs I             1.186 (0.642--2.192)   0.585
  Subtype III vs I            1.586 (1.082--2.325)   0.018
  Model Y+day SBP                                    
  Age, y                      1.099 (1.076--1.123)   \<0.001
  Body mass index, kg/m^2^    1.057 (1.004--1.114)   0.036
  Brachial SBP, mm Hg         1.043 (1.029--1.056)   \<0.001
  Heart rate, beats per min   1.044 (1.027--1.062)   \<0.001
  Diabetes mellitus           1.632 (1.081--2.462)   0.020
  locker                      1.613 (1.026--2.535)   0.038
  Creatinine, mg/dL           2.258 (1.285--3.969)   0.005
  Subtype II vs I             1.143 (0.611--2.139)   0.676
  Subtype III vs I            1.469 (0.924--2.335)   0.104

Model Y as in Table [4](#jah32051-tbl-0004){ref-type="table-wrap"}. High‐risk carotid to femoral pulse wave velocity (cfPWV) is defined as aortic cfPWV \>10 m/s. OR indicates odds ratio; SBP, systolic blood pressure.

Discussion {#jah32051-sec-0019}
==========

The present study made some important findings. First, in the cohort of patients at high risk for CVD, nearly 50% had morning hypertension, with 80% having nocturnal hypertension with morning hypertension. Second, morning hypertension with elevated nocturnal hypertension was associated with significant increases in the indices of central hemodynamics and vascular organ damage. Third, morning hypertension subtype III was independently associated with central hypertension and increased arterial stiffness.

The fact that nearly half of the study patients had morning hypertension has clinical significance in that despite control of office BP, elevated morning BP has been shown to be an adverse prognostic factor for both target organ damage and adverse cardiovascular outcomes.[6](#jah32051-bib-0006){ref-type="ref"}, [7](#jah32051-bib-0007){ref-type="ref"}, [8](#jah32051-bib-0008){ref-type="ref"}, [9](#jah32051-bib-0009){ref-type="ref"}, [16](#jah32051-bib-0016){ref-type="ref"} The reason for the higher prevalence of morning hypertension in this study (47.5%) compared with that reported in the HONEST study (16.5%)[8](#jah32051-bib-0008){ref-type="ref"}, [9](#jah32051-bib-0009){ref-type="ref"} may be related to the different definitions of morning hypertension (home morning SBP ≥145 mm Hg in the HONEST study), the difference in the use of ABPM, and the high cardiovascular risk of this cohort. The high prevalence of morning hypertension can also be explained by the fact that nocturnal hypertension and the nondipping pattern of nocturnal BP are highly prevalent in patients with diabetes mellitus or chronic kidney disease.[17](#jah32051-bib-0017){ref-type="ref"}, [18](#jah32051-bib-0018){ref-type="ref"}, [19](#jah32051-bib-0019){ref-type="ref"}, [20](#jah32051-bib-0020){ref-type="ref"} In a cross‐sectional analysis from the African American Study of Kidney Disease, the nondipping pattern was observed in 80% of the study participants, and 70% of 377 participants with well‐controlled office BP had masked hypertension. The results from this cohort support this finding as well.[17](#jah32051-bib-0017){ref-type="ref"} As such, the assessment of ambulatory BP to evaluate nocturnal hypertension and morning hypertension should be part of the routine management in patients at high risk for CVD.

Another key finding of this study was that sustained elevation of morning BP that extended from elevated nocturnal hypertension and not morning hypertension due to early morning surge was significantly associated with markers of aortic target organ damage. Previous studies also reported that target organ damage was more prevalent in patients with nocturnal hypertension.[17](#jah32051-bib-0017){ref-type="ref"} In addition, the J‐HOP study showed that morning hypertension was related to target organ damage indicators, such as urine albumin/creatinine ratio.[7](#jah32051-bib-0007){ref-type="ref"} Recent studies have shown that arterial stiffness and central hemodynamic load are independent prognostic predictors of adverse cardiovascular outcomes.[21](#jah32051-bib-0021){ref-type="ref"}, [22](#jah32051-bib-0022){ref-type="ref"} Growing evidence suggests that central BP may be more relevant than brachial BP for predicting target organ damage and cardiovascular outcomes.[15](#jah32051-bib-0015){ref-type="ref"}, [23](#jah32051-bib-0023){ref-type="ref"}, [24](#jah32051-bib-0024){ref-type="ref"}, [25](#jah32051-bib-0025){ref-type="ref"} Arterial stiffness is one of the earliest manifestations of adverse structural and functional changes within the arterial wall. It results in augmentation of the central aortic pressure in central hemodynamics.[22](#jah32051-bib-0022){ref-type="ref"} The significance of this study is that it is the first report to show the interrelationship of central hemodynamics and arterial stiffness with morning hypertension, especially the morning hypertension subtype associated with nocturnal hypertension.

There has been some controversy with regard to the clinical implications of morning hypertension, especially morning hypertension associated with morning BP surge. In the study by Verdecchia et al,[26](#jah32051-bib-0026){ref-type="ref"} which was a cohort study of 3012 patients followed up for a mean period of 8.44 years, blunted morning surge, rather than excessive morning surge, was associated with adverse cardiovascular events. In addition, a study by Bombelli et al[27](#jah32051-bib-0027){ref-type="ref"} reported that morning BP surge was not associated with cardiovascular death, all‐cause death, or target organ damage in a cohort of 2051 patients followed up for 16 years. In contrast, nocturnal hypertension has been consistently shown to be associated with adverse cardiovascular events and cardiovascular target organ damage.[2](#jah32051-bib-0002){ref-type="ref"}, [28](#jah32051-bib-0028){ref-type="ref"} As such, we can suggest that morning hypertension associated with elevated nocturnal BP may be a subtype with a higher risk of cardiovascular end organ damage and adverse events. It will be interesting to further reanalyze the negative results from the aforementioned study to determine the difference in clinical outcomes according to the morning hypertension subtypes.

Interestingly, subtype II patients did not show any significant difference in regional PWV using the Omron device but showed higher central SBP and cfPWV when compared with the findings in subtype I patients (Table [3](#jah32051-tbl-0003){ref-type="table-wrap"}). As there was a graded increase in central aortic stiffness from morning normotension to morning hypertension due to morning surge when compared with morning hypertension with nocturnal hypertension, our data may shed light on the different reports with regard to the prognostic significance of morning surge for cardiovascular outcomes. As the aortic PWV is higher for morning hypertension associated with nocturnal hypertension than for morning hypertension associated with morning surge, efforts to determine the subtypes of morning hypertension may be needed. This has important prognostic implications since chronotherapy to target both nocturnal hypertension and morning hypertension may reduce aortic stiffness and central aortic pressure.[29](#jah32051-bib-0029){ref-type="ref"}

The explanation for the different interaction of morning hypertension subtype with aortic stiffness is unclear. Previous studies have demonstrated a significant association of increased heart rate with PWV.[30](#jah32051-bib-0030){ref-type="ref"}, [31](#jah32051-bib-0031){ref-type="ref"} Although the mechanism behind this phenomenon has yet to be firmly established, passive decrease in arterial compliance due to reduced time for elastic recoil has been suggested to be an explanation for this phenomenon.[31](#jah32051-bib-0031){ref-type="ref"}, [32](#jah32051-bib-0032){ref-type="ref"} We postulate that the effect of nocturnal hypertension and morning hypertension on arterial stiffening is accentuated in arteries passively stiffened by increased baseline heart rate. With regard to the significant association of morning hypertension related to nocturnal hypertension with central aortic BP and aortic PWV, we postulate that the increased hemodynamic stress that is related to nocturnal/morning hypertension over time will result in increased aortic stiffness, which, in turn, will increase central aortic BP and vice versa.[29](#jah32051-bib-0029){ref-type="ref"} However, as this was a cross‐sectional analysis, we cannot rule out the possibility that increased aortic stiffness and central hemodynamic loads are responsible for elevated nocturnal hypertension and morning hypertension in these patients. According to previous trials such as the Conduit Artery Function Evaluation (CAFE) study,[33](#jah32051-bib-0033){ref-type="ref"} β‐blocker use may be related to impaired central hemodynamics in hypertensive patients.[34](#jah32051-bib-0034){ref-type="ref"} In our study, although more β‐blockers were used in patients with morning hypertension subtype III, β‐blocker administration was not an independent predictor for central hypertension in our adjusted model. Further, prospective analyses on the association between morning hypertension subtypes and progression of aortic stiffness are needed.

Study Strengths {#jah32051-sec-0020}
---------------

The strength of this study is that comprehensive assessment of markers of target organ damage and determination of their association with morning hypertension with or without nocturnal hypertension were performed in a relatively large cohort at high risk for CVD. However, our study had some limitations. First, owing to the cross‐sectional design of the study, we could not distinguish the cause‐effect relationship. Second, we could not evaluate the prognostic significance of the different morning hypertension subtypes. However, as this is an ongoing prospective longitudinal study, we will be able to address these issues in the future. Third, because this study was performed in a population with relatively high cardiovascular risk, the results of this study should be generalized with caution. A further study in patients with relatively low to moderate cardiovascular risk who are assumed to have morning hypertension subtype II (morning surge) will be interesting. Fourth, drug adherence and the administration timing of hypertensive medication could be important confounders. However, we were not able to analyze for drug adherence and thus could not control for it in the analysis. Finally, this study included only Korean individuals. A recent study reported ethnic differences in the degree of morning BP surge between Japanese and European hypertensive patients.[35](#jah32051-bib-0035){ref-type="ref"} Therefore, a further study to confirm our findings is warranted in Western populations.

Conclusions {#jah32051-sec-0021}
===========

We propose, for the first time, that morning hypertension, especially that associated with nocturnal hypertension, is related to an increased risk of cardiovascular target organ damage, especially central hemodynamics, such as higher central BP and increased arterial stiffness.
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